Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of ALG-055009 and Statins in Healthy Volunteers
NCT06191991Phase 1Completed
- Sponsor
- Aligos Therapeutics
- Start
- Nov 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ALG-055009 in metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Aligos Therapeutics. Primary endpoints: Area under the concentration time curve at 22 days, Time to maximum plasma concentration at 22 days and 3 more. Started Nov 2023; status: completed.
02
Drugs
ALG-055009
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06191991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191991.